Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML (OPAL)

This study has been completed.
Sponsor:
Collaborator:
Quintiles
Information provided by (Responsible Party):
Chroma Therapeutics
ClinicalTrials.gov Identifier:
NCT00780598
First received: October 24, 2008
Last updated: June 27, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2011
  Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
No publications provided by Chroma Therapeutics

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):